KORTUC has secured a $20M funding commitment to support operations through early 2027, advanced its registrational Phase II trial in breast cancer in partnership with the UK’s Institute of Cancer Research and leading cancer centers, and expanded its clinical pipeline to include cervical and rectal cancers across the US, EU, and Asia. We are preparing a rectal cancer trial in collaboration with Gustave Roussy in France and a cervical cancer trial with UC San Diego, UT Southwestern, and other leading cancer centers worldwide.
This is where a company's traction statement would be visible. As you are not logged in, you cannot see it. When you become an advisor you'll be able to view the traction.
CMC and regulatory strategy to prepare NDA submissions in the US and Europe; scaling up commercial production of our novel radiosensitizer; global pricing, market access, and commercialization strategy in oncology; partnerships with leading cancer centers and key opinion leaders; global marketing and sales execution; and strategic fundraising from venture capital, corporate, and institutional investors.
This is where you can find what a company would like mentoring on. The field will become available when you are onboarded.
